Elanco Animal Health Incorporated (ELAN) reported $1.24 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 4.8%. EPS of $0.26 for the same period compares to $0.30 a year ago.
The reported revenue represents a surprise of +4.67% over the Zacks Consensus Estimate of $1.19 billion. With the consensus EPS estimate being $0.20, the EPS surprise was +30%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Elanco Animal Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Total Pet Health: $643 million versus $601.9 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +11.1% change.
- Revenue- Total Contract Manufacturing: $15 million versus the four-analyst average estimate of $10.89 million. The reported number represents a year-over-year change of +36.4%.
- Revenue- Total Farm Animal: $583 million versus $573.69 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.9% change.
View all Key Company Metrics for Elanco Animal Health here>>>
Shares of Elanco Animal Health have returned -5.6% over the past month versus the Zacks S&P 500 composite's +1.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Elanco Animal Health Incorporated (ELAN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
